Counteracting bone fragility with human amniotic mesenchymal stem cells

• DOI: 10.1038/srep39656
• Publication Date: 2016-12-20T11:02:01Z
• Authors: Anna M. Ranzoni; Michelangelo Corc...; Kwan-Leong Hau; Jemma G. Kerns; Maximilien Vanleene; Sandra Shefelbine; Gemma N. Jones; Dafni Moschidou; Benan Dala-Ali; Allen E. Goodship; Paolo De Coppi; Timothy R. Arnett; Pascale V. Guillot
• Keywords: Bone remodeling; Bone cell

Abstract The impaired maturation of bone-forming osteoblasts results in reduced bone formation and subsequent weakening, which leads to a number conditions such as osteogenesis imperfecta (OI). Transplantation human fetal mesenchymal stem cells has been proposed skeletal anabolic therapy enhance formation, but the mechanisms underlying contribution donor health are poorly understood require further elucidation. Here, we show that intraperitoneal injection amniotic (AFSCs) into mouse model OI ( oim mice) fracture susceptibility, increased strength, improved quality micro-architecture, normalised remodelling TNFα TGFβ sigalling. Donor engrafted bones differentiated importantly, also promoted endogenous resident osteoblasts. Together, these findings identify AFSC transplantation countermeasure fragility. These data have wider implications for reduction.